January 19, 2017 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), was announced concerning whether the takeover of Ariad Pharmaceuticals, Inc. by Takeda Pharmaceutical Company Limited for $24.00 per share is unfair to NASDAQ:ARIA stockholders.

The investigation by a law firm concerns whether certain officers and directors of Ariad Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ:ARIA investors in connection with the proposed acquisition.

On January 9, 2017, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it has entered into an agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) under which Takeda Pharmaceutical Company will acquire all of the outstanding shares in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion,

However, the investigation concerns whether the offer is unfair to NASDAQ:ARIA stockholders. More specifically, the investigation concerns whether the Ariad Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported that its annual Total Revenue increased from $105.41 million in 2014 to $118.80 million in 2015 and that its Net Loss grew from $162.60 million in 2014 to $231.16 million in 2015.

On January 19, 2017, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) closed at $23.70 per share.